Drug Insight: Antioxidant therapy in inherited ataxias

Nature Clinical Practice Neurology

Volumn 4, Issue 2, 2008, Pages 86-96

  Pandolfo, Massimo ^a  

^a FREE UNIVERSITY OF BRUSSELS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ACONITATE HYDRATASE; ALPHA TOCOPHEROL; ANTIOXIDANT; DEFEROXAMINE; DEOXYGUANOSINE DERIVATIVE; FERROUS ION; FRATAXIN; GLUTATHIONE TRANSFERASE; IDEBENONE; MALONALDEHYDE; PLACEBO; RETINOIC ACID; SELENIUM; TEMPOL; UBIDECARENONE; UBIQUINONE; UBIQUINONE DERIVATIVE;

ALPHA TOCOPHEROL DEFICIENCY; ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; CEREBELLAR ATAXIA; CLINICAL ASSESSMENT; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FRIEDREICH ATAXIA; GENE MUTATION; HEREDITARY ATAXIA; HUMAN; HUNTINGTON CHOREA; LEUKOPENIA; LOW DRUG DOSE; MAXIMUM ALLOWABLE CONCENTRATION; MICROARRAY ANALYSIS; NEUROIMAGING; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT; VITAMIN SUPPLEMENTATION;

ANIMALS; ANTIOXIDANTS; HUMANS; OXIDATIVE STRESS; SPINOCEREBELLAR DEGENERATIONS;

EID: 39049121295     PISSN: 1745834X     EISSN: 17458358     Source Type: Journal    
DOI: 10.1038/ncpneuro0704     Document Type: Review

References (60)

1. Calabrese V et al. (2007) Redox regulation of cellular stress response in aging and neurodegenerative disorders: Role of vitagenes. Neurochem Res 32: 757-773
2. Calabrese V et al. (2006) Redox modulation of heat shook protein expression by acetylcamitine in aging brain: Relationship to antioxidant status and mitochondrial function. Antioxid Redox Signal 8: 404-416
3. Pandolfo M (2006) Friedreich ataxia. In Genetrc Intabilities and Neurological Diseases, edn 2 77-298 (Eds Wells RD and Ashizawa T) San Diego: Academic Press
4. Campuzano V et al. (1996) Friedreich ataxia: Autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 271:1423-1427
5. Sakamoto N et al. (1999) Sticky DNA: Self-association properties of long GAA.TTC repeats in R.R.Y triplex structures from Friedreidh's ataxia. Mol Cell 3; 465-475
6. Herman D et al. (2006) Histone deacetylase inhibitors reverse gene silendng in Friedreich's ataxia. Nat Chem Biol 2: 551-558
7. Babcock M et al. (1997) Regulation of mitochondrial iron accumulation by Yfh1, a putative homolog of frataxin. Science 276: 1709-1712
8. Cossée M et al. (2000) Inactivation of the Friedreich ataxia mouse gene leads to early embryonic lethality without iron accumulation. Hum Mol Genet 9: 1219-1226
9. Puccio H et al. (2001) Mouse models for Friedrech ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits. Nat Genet 27: 181-618
10. Pandolfo M (2006) Animal models of Friedreich ataxia. In Animal Models of Movement Disorders, 649-657 (Ed LeDoux M) London: Elsevier Academic Press
11. Rouault TA and Tong WH (2005) Iron-sulphur cluster biogenesis and mitochondrial iron homeostasis. Nat Rev Mol Cell Biol 6: 345-351
12. Martelli A et al. (2007) Frataxin is essential for extramitochondrial Fe-S cluster proteins in mammalian tissues. Hum Mol Genet [doi:10.1093/hmg/ddm163]
13. Yoon T and Cowan JA (2003) Iron-sulfur cluster biosynthesis: characterization of frataxin as an iron donor for assembly 9f [2Fe-2S] clusters in ISU-type proteins. J Am Chem Soc 125: 6078-6084
14. Radisky DC et al. (1999) The yeast frataxin homologue mediates mitochondrial iron efflux: Evidence for a mitochondrial iron cycle. J Biol Chem 274: 4497-4499
15. Chen OS et al. (2004) Transcription of the yeast-iron regulon does not respond directly to iron but rather to iron-sulfur cluster biosynthesis. J Biol Chem 279: 29513-29518
16. Wong A et al. (1999) The Friedreich ataxia mutation confers cellular sensitivity to oxidant stress which is rescued by chelators of iron and calcium and inhibitors of apoptosis. Hum Mol Genet 8 425-430
17. Bulteau AL et al. (2007) Oxidative stress and protease dysfunction in the yeast model of Friedreich ataxia. Free Radic Biol Med 42 1561-1570
18. Santos M et al. (2001) Frataxin deficiency enhances apoptosis in cells differentiating into neuroectoderm. Hum Mol Genet 10: 1935-1944
19. Pianese L et al. (2002) Up-regulation of c-Jun N-terminal kinase pathway in Friedreich's ataxia cells. Hum Mol Genet 11: 2989-2996
20. Jiralerspong S et al. (2001) Manganese superoxide dismutase induction by iron is impaired in Friedreich ataxia cells. FEBS Letters 509: 101-105
21. Chantrel-Groussard K et al. (2001) Disabled early recruitment of antioxidant defenses in Friedreich's ataxia. Hum Mol Genet 10 2061-2067
22. Emond M et al. (2000) Increased levels of plasma malondialdehyde in Friedreich ataxia. Neurology 55: 1752-1753
23. Schulz JB et al. (2000) Oxidative stress in patients with Friedreich ataxia. Neurology 55: 1719-1721
24. Tozzi G et al. (2002) Antioxidant enzymes in blood of patients with Friedreich's ataxia. Arch Dis Child 86: 376-379
25. Seznec H et al. (2005) Friedreich ataxia: The oxidative stress paradox. Hum Mol Genet 14: 463-474
26. Trouillas P et al. (1997) International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. The Ataxia Neuropharmacology Committee of the World Federation of Neuropharmacology J Neurol Sci 145:205-211
27. Subramony SH et al. (2005) Measuring Friedreich ataxia: Interrater reliability of a neurologic rating scale. Neurology 64: 1261-1262
28. Schmitz-Hubsch T et al. (2006) Scale for the assessment and rating of ataxia: Development of a new clinical scale. Neurology 66 1717-1720
29. Lodi R et al. (1999) Deficit of in vivo mitochondrial ATP production in patients with Friedreich ataxia. Proc Natl Aced Sci USA 96: 11492-11495
30. Hart PE et al. (2005) Antioxidant treatment of patients with Friedreich ataxia: Four-year follow-up. Arch Neurol 62 621-626
31. Banaclocha MM (2001) Therapeutic potential of N-acetylcysteine in age-related neurodegenerative mitochondrial diseases. Med Hypotheses 56: 472-477
32. Sugiyama Y and Fujita T (1985) Stimulation of the respiratory and phosphorylating activities in rat brain mitochondria by idebenone (CV-2619), a new agent improving cerebral metabolism. FEBS Letters 184: 48-51
33. Brière JJ et al. (2004) Quinone analogues regulate mitochondrial substrate competitive oxidation.. Biochem Biophys Res Comm 316:1138-1142
34. Sugiyama Y et al. (1985) Effects of idebenone (CV-2169) and its metabolites on respiratory activity and lipid peroxidation in brain mitochondria from rats and dogs. J Pharmacobiodyn 8: 1006-1017
35. Weyer G et al. (1997) A controlled study of-2 doses of idebenone in the treatment of Alzheimer's disease. Neuropsychobiology 36 73-82
36. Thai LJ et al. (2003) Idebenone treatment fails to slow cognitive decline in Alzheimer's disease. Neurology 61: 1498-1502
37. Ranen NG et al. (1996) A controlled trial of idebenone in Huntington's disease. Mov Disord 11: 549-554
38. Rustin P et al. (1999) Effect at idebenone on cardiomyopathy in Friedreich's ataxia: A preliminary study. Lancet 354: 477-479
39. Mariotti C et al. (2003) Idebenone treatment in Friedreich patients: One-year-long randomized placebo-controlled trial. Neurology 60: 1676-1679
40. Ribai P et al. (2007) Neurological, cardiological, and oculomotor progression in 104 patients with Friedreich ataxia during long-term follow-up. Arch Neurol 64: 558-664.
41. Seznec H et al. (2004) Idebenone delays the onset of cardiac functional alteration without correction of Fe-S enzymes deficit in a mouse model for Friedreich ataxia. Hum Mol Genet 13:1017-1024
42. Artuch R et al. (2004) Cerebrospinal fluid concentrations of idebenone in Friedleich ataxia patients. Neuropediatrics 35: 95-98
43. Di Prospero NA et al. (2007) Safety, tolerability, and pharmacokinetics of high-dose idebenone administered to patients with Friedreich's ataxia. Arch Neurol 64: 803-808
44. Di Prospero N et al. (2007) Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: A randomised placebo-controlled trial. Lancet Neurol 6: 878-886
45. Tauskela JS (2007) MitoQ-a mitochondria-targeted antioxidant. IDrugs 10: 399-412
46. Pandolfo M and Dupondt C (2W7) Friedreich's ataxia and related loss-of-function disorders. In Molecular Neurology, 277-294 (Ed Waxman SG) San Diego: Academic Press
47. Hirano M et al. (2007) DNA single-strand break repair is impaired in aprataxin-related ataxia. Ann Neurol 61: 162-174.
48. Suraweera A et al. (2007) Senataxin, defective in ataxia oculomotor apraxia type 2 is involved in the defense against oxidative DNA damage. J Cell Biol 177: 969-979
49. Ziv S et al. (2005) Impaired genomic stability and increased oxidative stress exacerbate different features of ataxia-telangiectasia. Hum Mol Genet 14: 2929-2943
50. Gueven M et al. (2006) Dramatic extension of tumor latency and correction of neurobehavioral phenotype in Atm-mutant mice with a nitroxide antioxidant. Free Radic Biol Med 41: 992-1000
51. Erker L et al. (2006) Effect of the reduction of superoxide dismutase 1 and 2 or treatment with alpha-tocopherol on tumorigenesis in Atm-deficient mice. Free Radic Biol Med 41: 590-600
52. Soong BW and Paulson HL (2007) Spinocerebellar ataxias: An update. Curr Opin Neurol 20:438-446
53. Bates GP and Hockly E (2003) Experimental therapeutics in Huntington's disease: Are models useful for therapeutic trials? Curr Opin Neurol 16: 465-470
54. Artuch R et al. (2006) Cerebellar ataxia with coenzyme Q10 deficiency: Diagnosis and follow-up after coenzyme Q10 supplementation. J Neurol Sci 246: 163-158
55. Mattiazzi M et al. (2004) The mtDNA T8993G (NARP) mutation results in an impairment of oxidative phosphorylation that can be improved by antioxidants. Hum Mol Genet 13 869-879
56. Schulz JB et al. (2000) Oxidative stress in patients with Friedreich's ataxia. Neurology 55: 1719-1721
57. Artuch R et al. (2002) Friedreich's ataxia: Idebenone treatment in early stage patients. Neuropediatrics 33: 130-193
58. Hausse AO et al. (2002) Idebenone and reduced cardiac hypertrophy in Friedreich's ataxia. Heart 87: 346-349
59. Rustin P et al. (2002) Heart hypertrophy and function are improved by idebenone in Friedreich's ataxia. Free Radic Res 36: 467-469
60. Buyse G et al. (2003) Idebenone treatment in Friedreich's ataxia: neurological, cardiac, and biochemical monitoring. Neurology 60 1679-1681